Preliminary Report of the Safety and Efficacy of Hyperbaric Oxygen Therapy for Specific Complications of Lung Transplantation

Takao Higuchi, Takahiro Oto, Ian L. Millar, Bronwyn J. Levvey, Trevor J. Williams, Gregory I. Snell

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Lung transplantation (LTx) is a complex therapy requiring immunosuppression and is associated with significant infective morbidity and mortality. Hyperbaric oxygen (HBO) therapy has been used successfully in the treatment of specific serious infections, ischemic injuries and cerebral arterial gas embolism. The purpose of this study was to evaluate the efficacy and safety of HBO therapy after LTx, generally as indicated for refractory infectious complications. Methods: This investigation was a retrospective study of all lung transplant recipients treated with HBO therapy at the Alfred Hospital between March 1990 and August 2005. Results: In this study we describe 9 patients (1.7%) from a total of 544 overall lung transplants performed over the period. Indications included: sternal osteomyelitis (n = 4); refractory cellulitis (n = 2); refractory septic arthritis (n = 1); ischemic toes (n = 1); and cerebral arterial gas embolism (n = 1). The patients received 1 to 25 HBO treatments at 100% Fio2 and 100 to 180 kPa for 100 minutes per treatment. The treatment was generally well tolerated, although 2 patients ceased therapy prematurely due to a seizure and ear barotrauma (n = 1 each). Five patients had complete resolution of these life-threatening complications. Long-term survival and graft function were excellent, although graft function temporarily fell. Conclusions: HBO is a safe therapy for traditional HBO indications after LTx and appears useful, particularly in the management of infectious complications, whereas other therapies have failed or are contraindicated.

Original languageEnglish
Pages (from-to)1302-1309
Number of pages8
JournalJournal of Heart and Lung Transplantation
Volume25
Issue number11
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Hyperbaric Oxygenation
Lung Transplantation
Safety
Air Embolism
Therapeutics
Oxygen
Barotrauma
Transplants
Lung
Infectious Arthritis
Cellulitis
Toes
Graft Survival
Osteomyelitis
Immunosuppression
Ear
Seizures
Retrospective Studies
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Preliminary Report of the Safety and Efficacy of Hyperbaric Oxygen Therapy for Specific Complications of Lung Transplantation. / Higuchi, Takao; Oto, Takahiro; Millar, Ian L.; Levvey, Bronwyn J.; Williams, Trevor J.; Snell, Gregory I.

In: Journal of Heart and Lung Transplantation, Vol. 25, No. 11, 11.2006, p. 1302-1309.

Research output: Contribution to journalArticle

Higuchi, Takao ; Oto, Takahiro ; Millar, Ian L. ; Levvey, Bronwyn J. ; Williams, Trevor J. ; Snell, Gregory I. / Preliminary Report of the Safety and Efficacy of Hyperbaric Oxygen Therapy for Specific Complications of Lung Transplantation. In: Journal of Heart and Lung Transplantation. 2006 ; Vol. 25, No. 11. pp. 1302-1309.
@article{0dc9e7d1b74d42ea8afa999572883a23,
title = "Preliminary Report of the Safety and Efficacy of Hyperbaric Oxygen Therapy for Specific Complications of Lung Transplantation",
abstract = "Background: Lung transplantation (LTx) is a complex therapy requiring immunosuppression and is associated with significant infective morbidity and mortality. Hyperbaric oxygen (HBO) therapy has been used successfully in the treatment of specific serious infections, ischemic injuries and cerebral arterial gas embolism. The purpose of this study was to evaluate the efficacy and safety of HBO therapy after LTx, generally as indicated for refractory infectious complications. Methods: This investigation was a retrospective study of all lung transplant recipients treated with HBO therapy at the Alfred Hospital between March 1990 and August 2005. Results: In this study we describe 9 patients (1.7{\%}) from a total of 544 overall lung transplants performed over the period. Indications included: sternal osteomyelitis (n = 4); refractory cellulitis (n = 2); refractory septic arthritis (n = 1); ischemic toes (n = 1); and cerebral arterial gas embolism (n = 1). The patients received 1 to 25 HBO treatments at 100{\%} Fio2 and 100 to 180 kPa for 100 minutes per treatment. The treatment was generally well tolerated, although 2 patients ceased therapy prematurely due to a seizure and ear barotrauma (n = 1 each). Five patients had complete resolution of these life-threatening complications. Long-term survival and graft function were excellent, although graft function temporarily fell. Conclusions: HBO is a safe therapy for traditional HBO indications after LTx and appears useful, particularly in the management of infectious complications, whereas other therapies have failed or are contraindicated.",
author = "Takao Higuchi and Takahiro Oto and Millar, {Ian L.} and Levvey, {Bronwyn J.} and Williams, {Trevor J.} and Snell, {Gregory I.}",
year = "2006",
month = "11",
doi = "10.1016/j.healun.2006.08.006",
language = "English",
volume = "25",
pages = "1302--1309",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Preliminary Report of the Safety and Efficacy of Hyperbaric Oxygen Therapy for Specific Complications of Lung Transplantation

AU - Higuchi, Takao

AU - Oto, Takahiro

AU - Millar, Ian L.

AU - Levvey, Bronwyn J.

AU - Williams, Trevor J.

AU - Snell, Gregory I.

PY - 2006/11

Y1 - 2006/11

N2 - Background: Lung transplantation (LTx) is a complex therapy requiring immunosuppression and is associated with significant infective morbidity and mortality. Hyperbaric oxygen (HBO) therapy has been used successfully in the treatment of specific serious infections, ischemic injuries and cerebral arterial gas embolism. The purpose of this study was to evaluate the efficacy and safety of HBO therapy after LTx, generally as indicated for refractory infectious complications. Methods: This investigation was a retrospective study of all lung transplant recipients treated with HBO therapy at the Alfred Hospital between March 1990 and August 2005. Results: In this study we describe 9 patients (1.7%) from a total of 544 overall lung transplants performed over the period. Indications included: sternal osteomyelitis (n = 4); refractory cellulitis (n = 2); refractory septic arthritis (n = 1); ischemic toes (n = 1); and cerebral arterial gas embolism (n = 1). The patients received 1 to 25 HBO treatments at 100% Fio2 and 100 to 180 kPa for 100 minutes per treatment. The treatment was generally well tolerated, although 2 patients ceased therapy prematurely due to a seizure and ear barotrauma (n = 1 each). Five patients had complete resolution of these life-threatening complications. Long-term survival and graft function were excellent, although graft function temporarily fell. Conclusions: HBO is a safe therapy for traditional HBO indications after LTx and appears useful, particularly in the management of infectious complications, whereas other therapies have failed or are contraindicated.

AB - Background: Lung transplantation (LTx) is a complex therapy requiring immunosuppression and is associated with significant infective morbidity and mortality. Hyperbaric oxygen (HBO) therapy has been used successfully in the treatment of specific serious infections, ischemic injuries and cerebral arterial gas embolism. The purpose of this study was to evaluate the efficacy and safety of HBO therapy after LTx, generally as indicated for refractory infectious complications. Methods: This investigation was a retrospective study of all lung transplant recipients treated with HBO therapy at the Alfred Hospital between March 1990 and August 2005. Results: In this study we describe 9 patients (1.7%) from a total of 544 overall lung transplants performed over the period. Indications included: sternal osteomyelitis (n = 4); refractory cellulitis (n = 2); refractory septic arthritis (n = 1); ischemic toes (n = 1); and cerebral arterial gas embolism (n = 1). The patients received 1 to 25 HBO treatments at 100% Fio2 and 100 to 180 kPa for 100 minutes per treatment. The treatment was generally well tolerated, although 2 patients ceased therapy prematurely due to a seizure and ear barotrauma (n = 1 each). Five patients had complete resolution of these life-threatening complications. Long-term survival and graft function were excellent, although graft function temporarily fell. Conclusions: HBO is a safe therapy for traditional HBO indications after LTx and appears useful, particularly in the management of infectious complications, whereas other therapies have failed or are contraindicated.

UR - http://www.scopus.com/inward/record.url?scp=33750630375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750630375&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2006.08.006

DO - 10.1016/j.healun.2006.08.006

M3 - Article

VL - 25

SP - 1302

EP - 1309

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 11

ER -